SEC Form 4 · accession 0000899243-18-011942
Amneal Pharmaceuticals, Inc. · AMRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bryan M. Reasons
Officer — CFO
Period of report
May 4, 2018
Accepted (ET)
May 8, 2018 · 7:22 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001723128
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common StockF1 | May 4, 2018 | A | 94,684 | — | A | 94,684 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF3,F2 | $9.35 | May 4, 2018 | A | 56,232 | A | — | Mar 2, 2027 | Class A Common Stock | 56,232 | 56,232 | D |
| Stock OptionF3,F2 | $33.27 | May 4, 2018 | A | 63,095 | A | — | Feb 26, 2026 | Class A Common Stock | 63,095 | 63,095 | D |
| Stock OptionF3,F2 | $40.70 | May 4, 2018 | A | 47,500 | A | — | Feb 26, 2025 | Class A Common Stock | 47,500 | 47,500 | D |
| Stock OptionF3,F2 | $25.24 | May 4, 2018 | A | 55,000 | A | — | May 14, 2024 | Class A Common Stock | 55,000 | 55,000 | D |
| Stock OptionF3,F2 | $17.99 | May 4, 2018 | A | 52,000 | A | — | May 15, 2023 | Class A Common Stock | 52,000 | 52,000 | D |
| Stock OptionF4 | $15.01 | May 7, 2018 | A | 136,240 | A | — | May 7, 2028 | Class A Common Stock | 136,240 | 136,240 | D |
| Restricted Stock UnitsF5,F6 | — | May 7, 2018 | A | 33,311 | A | — | — | Class A Common Stock | 33,311 | 33,311 | D |
Explanation of responses
- F1Received in exchange for 94,684 shares of Impax Laboratories, Inc. ("Impax") common stock pursuant to the Business Combination Agreement, dated as of October 17, 2017, among Impax, Amneal Pharmaceuticals LLC, Atlas Holdings, Inc. and K2 Merger Sub Corporation (as amended, the "BCA").
- F2The option is vested and currently exercisable.
- F3Received pursuant to the BCA in exchange for an option to purchase an equal number of shares of Impax common stock.
- F4The option vests in four equal annual installments beginning on May 07, 2019.
- F5Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
- F6The restricted stock units vest in four equal annual installments beginning on May 07, 2019 and have no expiration date.